Louis Moore Bacon's ALNY Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 4.1K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $1.87 M, representing 0.03% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Louis Moore Bacon has maintained a long-term strategic position in ALNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2022, adding 15.7K shares. Largest reduction occurred in Q4 2023, reducing 17.4K shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Louis Moore Bacon
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2015 | +5,500 | New Buy | 5,500 | $104.36 |
| Q2 2015 | -5,500 | Sold Out | 5,500 | $0.00 |
| Q3 2022 | +21,247 | New Buy | 21,247 | $200.17 |
| Q4 2022 | -11,247 | Reduce 52.93% | 10,000 | $237.65 |
| Q1 2023 | -10,000 | Sold Out | 10,000 | $0.00 |
| Q3 2023 | +21,985 | New Buy | 21,985 | $177.10 |
| Q4 2023 | -17,350 | Reduce 78.92% | 4,635 | $191.41 |
| Q1 2024 | -4,635 | Sold Out | 4,635 | $0.00 |
| Q3 2025 | +4,104 | New Buy | 4,104 | $456.00 |
Louis Moore Bacon's Alnylam Pharmaceuticals Investment FAQs
Louis Moore Bacon first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q1 2015, acquiring 5,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Alnylam Pharmaceuticals, Inc. (ALNY) for 43 quarters since Q1 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q3 2023, adding 21,985 shares worth $3.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 4,104 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $1.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 21,985 shares, as reported at the end of Q3 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.